Previous 10 | Next 10 |
NEW HAVEN, Conn., April 24, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) announces the launch of Precipio’s global pathology services. The services are intended to create a renewed and enhanced revenue stream by monetizing the expertise...
NEW HAVEN, Conn., April 18, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) announced today that Mr. Ori Karev has joined the company as its Chief Strategy Officer. Ori was formerly CEO of UnitedHealthcare Global , the International division o...
NEW HAVEN, Conn., April 15, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) will be hosting its 2018 year-end corporate update call on Monday, May 6 at 5:00 PM ET, following the expected filing on April 16 of its form 10-K and re...
NEW HAVEN, Conn., April 09, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) announced today that it is negotiating a definitive agreement with a manufacturer to produce its IV-Cell media. Over the past year, Precipio has been working to commer...
NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that Methodist Hospital , located in Memphis, TN, has selected Precipio’s HemeScreen assay for use in its molecular hematology testing laborato...
NEW HAVEN, Conn., March 27, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ) today announced that it has received the expected delisting determination from Nasdaq Staff. The Company has subsequently filed a request for a hearing before the Nasdaq ...
NEW HAVEN, Conn., March 11, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), issues the following letter from CEO Ilan Danieli. Dear Shareholders, Following our recent quarterly conference call, I would like to provide additional information...
NEW HAVEN, Conn., March 05, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today that it continues to receive both new and repeat business from customers in Japan for its ICP liquid biopsy enrichment technology. In Particular, Precipi...
NEW HAVEN, Conn., Feb. 18, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), will host a conference call on Thursday, February 21 st , 2019 at 4:30pm to review financial results and provide a corporate update. During the call, as a recap to ...
NEW HAVEN, Conn., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced today its preliminary unaudited 2018 Revenues of $2.8M, representing 66% growth over 2017 Revenues of $1.7M. Furthermore, fourth quarter financials demonstrat...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to e...